Let me guess. You've spent the last two evenings reading forum threads, PDF benefit summaries, and pharmacy comparison charts. You've bookmarked six different price calculators. You still don't know what your GLP-1 treatment will actually cost you.
Welcome to the club.
I'm Paul Moss, co-founder of tb2.health and — as I like to remind people — patient zero of our own program. When I started looking into GLP-1 coverage for myself, I did what you're probably doing now: I tried to solve the whole puzzle at once. Every payer. Every formulary. Every prior authorization form. It was a spectacular waste of a weekend.
Here's what I wish someone had told me: the entire cost-and-coverage conversation collapses into three questions. Answer those, and you know where you stand. Skip them, and you'll drown in the noise.
Why coverage feels impossible to pin down
Before we get into the three questions, a quick reality check.
GLP-1 medications originally came to market for type 2 diabetes. Coverage rules were built around that indication. Then the same drug class was approved for chronic weight management, and payers — commercial insurers, Medicare, Medicaid, employer plans — reacted in wildly different ways. Some cover weight-loss use. Many still don't. Some cover it only after you've failed other interventions. Some cover the medication but not the clinical program around it.
KFF's health policy tracking has documented how uneven this landscape is, and the Centers for Medicare & Medicaid Services has been explicit that Medicare Part D is statutorily restricted from covering drugs used for weight loss alone — a rule that shapes downstream commercial behavior too.
So if you feel like the rules keep shifting under you, it's because they do. The rules are also different for you than they are for your neighbor with a different employer and a different diagnosis. Averages won't help you. Your three answers will.
I'm not a clinician, and I'm certainly not your benefits administrator. But I've walked hundreds of prospective patients through this, and the same three questions cut through the fog every time.
Question 1: What is my plan's stance on GLP-1 for weight management specifically?
Not GLP-1 in general. Not GLP-1 for diabetes. GLP-1 for chronic weight management.
This is the fork in the road. Plans generally fall into one of four buckets:
| Plan stance | What it usually means for you |
|---|---|
| Covers weight-management indication | Prior authorization likely required; you'll need documented BMI and often comorbidities |
| Covers diabetes indication only | Weight-loss use is out-of-pocket or via a cash-pay program |
| Excludes anti-obesity medications entirely | No coverage regardless of medical necessity; cash-pay is your path |
| Employer carve-out or rider | Coverage exists but sits outside standard pharmacy benefits — call HR, not the insurer |
How to find your answer: call the member services number on the back of your card and ask, in exactly these words, "Does my plan cover GLP-1 receptor agonists for chronic weight management, and if so, what are the prior authorization criteria?" Write down the reference number for the call. You'll want it later.
If they say yes, move to question two. If they say no, skip to question three — it's actually the more important one for you.
Question 2: What does the prior authorization actually require?
"Covered" and "you'll get it filled next week" are not the same sentence.
Prior authorization (PA) is the gate. Typical PA criteria for weight-management GLP-1 coverage include some combination of:
- A documented BMI threshold (often ≥30, or ≥27 with a weight-related comorbidity)
- Evidence of prior weight-loss attempts (diet, exercise, sometimes a formal program)
- No contraindications on your medical history
- Ongoing clinical supervision — which is where a program like ours fits in
- Periodic reauthorization based on progress metrics
The American Medical Association has been vocal about how PA burdens delay care, and the Obesity Medicine Association publishes clinical guidelines that many payer PA forms are built around. Worth a skim if you like knowing what the rubric looks like before you take the test.
At tb2.health, when we onboard a patient who wants to use insurance, we handle the clinical documentation side — chart notes, BMI verification, comorbidity coding, the progress-monitoring cadence payers want to see. What we cannot do is change what your plan requires. Nobody can. The question is whether you meet the criteria, and how efficiently the documentation gets in front of the reviewer.
Question 3: What is the real out-of-pocket path if insurance is a no?
This is the question most people avoid because it feels like defeat. It isn't. For a large share of prospective patients, the cash-pay path is faster, more predictable, and — once you add up the copays, PA delays, and reauthorization drama — sometimes not much more expensive on a monthly basis.
When I talk to prospects who've been told "no" by their plan, I walk them through three cash-pay realities:
1. Manufacturer direct programs. Some manufacturers now sell certain doses directly to patients at a set monthly price outside the insurance system. Availability varies by dose and product.
2. Medically-supervised telehealth programs. This is what we do at tb2.health. A flat program fee covers the clinician visits, the ongoing supervision, side-effect management, and the labs/monitoring that make GLP-1 therapy safe. Medication cost is separate and transparent. No PA. No surprise reauthorization letters six months in.
3. Self-directed sourcing. I'll be blunt: I don't recommend this and neither does anyone with a license. The gap between medically-supervised and self-directed GLP-1 use isn't just a safety gap — it's a cost gap once something goes sideways. The FDA has warned repeatedly about compounded and unverified sources, and it's exactly the scenario I built our program to give people an alternative to.
For a deeper look at how supervision reshapes the risk/cost math, our friends at Growaton have written thoughtfully about the broader economics of physician-supervised metabolic care — worth the read if you're weighing options.
Putting the three answers together
Once you have all three, your next step becomes obvious:
- Yes to Q1, clear Q2 criteria you meet: Pursue insurance. Bring a program that handles the clinical documentation.
- Yes to Q1, Q2 criteria you don't yet meet: Ask what documentation would get you there, or start with cash-pay and reassess at renewal.
- No to Q1: Go to Q3. Compare a real medically-supervised program cost against the real total cost of alternatives, not just the sticker price of the medication.
The mistake I see people make over and over is stopping at Q1. They hear "not covered" and either give up or dive into risky self-sourced options. Neither is the answer. There's a middle path, and it's usually the one that makes sense financially once you actually sit down and do the math.
A note on what supervision covers that a prescription doesn't
Whether you go through insurance or cash-pay, you're not just buying a medication. You're buying — or should be buying — the clinical wrapper around it:
- Baseline labs and screening for contraindications
- Titration guidance and side-effect management
- Nutrition and protein-intake coaching so you preserve muscle, not just lose weight
- Progress monitoring that catches problems early
- A clinician you can actually reach when your third dose lands weird
When people ask me why our program isn't the cheapest line item they could find, that list is the answer. The medication is the tool. The supervision is what makes the tool safe and effective over the twelve, eighteen, twenty-four months you're actually going to be on it.
The clinician caveat
Everything above is meant to help you think clearly about coverage and cost. It is not medical advice, and it is not benefits advice. Your specific plan documents, your specific medical history, and your specific clinician's judgment are what determine whether GLP-1 therapy is right for you and how it should be structured. Before you act on any of this, talk to a licensed clinician — ours, or someone else's. That's not a legal disclaimer. That's the whole point of doing this the right way.
You're closer to an answer than you think
If you take one thing from this: the coverage maze feels infinite because you're trying to solve it in the abstract. It isn't infinite. It's three questions, and your version of the answers is probably a fifteen-minute phone call and one conversation with a clinician away.
Make the call. Get the reference number. Then decide. If you'd like us to walk it through with you, that's what we're here for.
You've already done the hard part, which is deciding you want to change something. The rest is logistics.
